Gurnet Point Capital and Patient Square Capital are buying biopharmaceutical company Radius Health for $890 million. Radius shareholders will receive $10 per share. Also, if abaloparatide reaches $300 million in TTM sales by December 31, 2025, shareholders will receive another $1 for each share. The transaction is expected to close in Q3 2022.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept